about
Targeting MDM2 by the small molecule RITA: towards the development of new multi-target drugs against cancer.Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53The role of p53 in cancer drug resistance and targeted chemotherapyTumor suppressor and hepatocellular carcinomaRegulation of GAD65 expression by SMAR1 and p53 upon Streptozotocin treatmentA decade and a half of protein intrinsic disorder: biology still waits for physicsUnderstanding protein non-folding.Microarray and ChIP-seq data analysis revealed changes in p53-mediated transcriptional regulation in Nutlin-3-treated U2OS cellsA simple technique for the prediction of interacting proteins reveals a direct Brn-3a-androgen receptor interaction.Phytochemicals Approach for Developing Cancer Immunotherapeutics.P53 mdm2 inhibitors.Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.A natural small molecule harmine inhibits angiogenesis and suppresses tumour growth through activation of p53 in endothelial cells.MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53.Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP.Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cellsTowards an understanding of the role of p53 in adrenocortical carcinogenesis.How To Design a Successful p53-MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures.Structural Disorder within Paramyxoviral Nucleoproteins and Phosphoproteins in Their Free and Bound Forms: From Predictions to Experimental Assessment.Targeting intrinsically disordered proteins in neurodegenerative and protein dysfunction diseases: another illustration of the D(2) concept.The MDM2-p53 pathway revisitedMutation analysis of 24 known cancer genes in the NCI-60 cell line set.Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy.Novel HIV-1 therapeutics through targeting altered host cell pathways.p53 modulates the activity of the GLI1 oncogene through interactions with the shared coactivator TAF9.Efficient co-delivery of a Pt(IV) prodrug and a p53 activator to enhance the anticancer activity of cisplatin.Interaction of an anticancer peptide fragment of azurin with p53 and its isolated domains studied by atomic force spectroscopy.An extra dimension in protein tagging by quantifying universal proteotypic peptides using targeted proteomics.Positional effects of click cyclization on β-hairpin structure, stability, and function.Interferon-inducible protein IFIXalpha1 functions as a negative regulator of HDM2.Unbalancing p53/Mdm2/IGF-1R axis by Mdm2 activation restrains the IGF-1-dependent invasive phenotype of skin melanoma.Coumarin-chalcone hybrid instigates DNA damage by minor groove binding and stabilizes p53 through post translational modifications.Anoikis triggers Mdm2-dependent p53 degradation.The C terminus of p53 binds the N-terminal domain of MDM2.Artificial Macrocycles as Potent p53-MDM2 Inhibitors.Chalcoplatin, a dual-targeting and p53 activator-containing anticancer platinum(IV) prodrug with unique mode of action.Screening for Protein-Protein Interaction Inhibitors Using a Bioluminescence Resonance Energy Transfer (BRET)–Based Assay in YeastIdentification of new inhibitors of Mdm2–p53 interaction via pharmacophore and structure-based virtual screening
P2860
Q24814753-4216066C-F820-4496-8D4B-CC276D5C1433Q27006998-A00E590F-47A3-4E2D-8B38-483ED007E632Q28072553-2EBC99AB-7CB7-44EB-8C36-8F37B56EDF8BQ28389231-625FD0AE-CB97-42EB-AA51-51AA84033058Q28593228-EA4651EA-E46A-4248-8754-0445B505402CQ28681184-B20530B2-A074-4454-9E3B-53645B2DF2ACQ30385084-3A38D227-47B7-4FFE-ADEC-3404C9BE3EF3Q30973420-D9681241-2226-4663-9F64-A77E2CD9D024Q33540587-97B4F8B6-A752-4273-9C3E-110F6BD028DDQ33809573-EC68DD98-8C82-4F20-AE61-1BC3252DEB64Q34287830-00C55658-C9B7-45B5-99D7-3B894EBEFC26Q34458379-0145F28A-58D1-443F-9062-3CAD9BB1264EQ34540424-E641CBDE-8D3F-430D-BE01-2F2AF164D67FQ34999483-62F82D8B-431C-45FE-B907-C3EBEE80FAF4Q35011473-AB61D642-B126-45AF-963A-630BE9C217DCQ35184378-812859A7-4C54-498D-8F68-58A07D50C6C1Q35783751-67B40D3C-94C4-4A65-A592-25E14351103BQ35871210-44FB0F91-E0E7-4B46-8562-7FF627CCA5CAQ35902551-394F77EE-88A1-4721-BB29-8523EB9BE8D3Q36020398-631D8FA4-5853-417B-B329-47601112B631Q37039474-A0B7551B-42A9-4F4B-88F5-7368E0ED60BEQ37250634-AD7BA148-5031-481E-A354-BF486B3FA545Q37257435-08B4951F-D171-4B89-9FCA-B958039887F8Q37445903-36EAAD2E-8DF3-4A3D-825B-5E5225905B83Q38843084-197765FE-C36E-4A68-878E-40E12260B178Q38889630-C8998490-3A1B-4F3C-8929-211E9A9FAA67Q39598993-F3838C01-E73C-4970-9171-3DA4901E7852Q39708053-2C7C91AD-B92E-4A12-B9DB-9776C824845FQ40029300-6AA02EB6-9EAD-4A46-99F4-D7979F1AF385Q41412965-49B34F5F-B911-4FCF-933E-FE213B88AF39Q42119362-00DF9CEB-FB73-4EA6-932F-3B10B15F475FQ42371971-7DFF63FE-A782-426C-864D-2D07919DF0F3Q42423622-2412A1B8-9A79-4C00-963A-848C790F8E5AQ42532759-ADBB2991-800E-4F45-8B74-2829370ED38DQ47117285-E4BB38B8-ABDD-4F26-A42F-0A3EDD8208FAQ52970552-07EFEBE6-AF5D-4EA9-92BD-8E2766D12157Q58667945-B8B6B8A5-4F39-4F0E-B9DD-8B9A5E146122Q59125760-70926AEF-7CEB-401B-9B66-A0EBB980C32A
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Targeting the p53-MDM2 interaction to treat cancer.
@ast
Targeting the p53-MDM2 interaction to treat cancer.
@en
type
label
Targeting the p53-MDM2 interaction to treat cancer.
@ast
Targeting the p53-MDM2 interaction to treat cancer.
@en
prefLabel
Targeting the p53-MDM2 interaction to treat cancer.
@ast
Targeting the p53-MDM2 interaction to treat cancer.
@en
P2860
P921
P356
P1476
Targeting the p53-MDM2 interaction to treat cancer.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6602164
P407
P577
2004-10-01T00:00:00Z
2004-10-18T00:00:00Z